

Superoxide Dismutase [Cu-Zn] - Pipeline Review, H2 2019

<https://marketpublishers.com/r/S4D3F7699E49EN.html>

Date: December 2019

Pages: 79

Price: US\$ 3,500.00 (Single User License)

ID: S4D3F7699E49EN

Abstracts

Superoxide Dismutase [Cu-Zn] - Pipeline Review, H2 2019

SUMMARY

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Superoxide Dismutase [Cu-Zn] - Pipeline Review, H2 2019, outlays comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O₂⁻) radical into either ordinary molecular oxygen (O₂) or hydrogen peroxide (H₂O₂) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 1, 9 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis,

Neurodegenerative Diseases, Parkinson's Disease and Wilson Disease.

Furthermore, this report also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)

The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretary Protein Li 44 or SOD1 or EC 1.15.1.1) - Overview

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretary Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretary Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretary Protein Li 44 or SOD1 or EC 1.15.1.1) - Companies Involved in Therapeutics Development

AL-S Pharma AG

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Apic Bio Inc

AveXis Inc

Biogen Inc

Collaborative Medicinal Development LLC

Priavoid GmbH

ProMIS Neurosciences Inc

Thera Neuropharma Inc

Trucode Gene Repair Inc

Voyager Therapeutics Inc

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretary Protein Li 44 or SOD1 or EC 1.15.1.1) - Drug Profiles

Antisense RNAi Oligonucleotides to Inhibit Superoxide Dismutase for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APB-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVXS-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Activate SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMN-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMN-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMN-130 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDI-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tiomolibdate choline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofersen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VYSOD-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VYSOD-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Dormant Products

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory

Protein Li 44 or SOD1 or EC 1.15.1.1) - Product Development Milestones

Featured News & Press Releases

Oct 16, 2019: Neurimmune and TVM Capital Life Science announce the initiation of ALS Pharma's phase 1 study of AP-101 for the treatment of ALS

Oct 14, 2019: Collaborative Medicinal Development enrolls first patient in a randomized, placebo-controlled clinical trial of CuATSM for The treatment of Amyotrophic Lateral Sclerosis

Jul 22, 2019: Apic Bio's APB-102 receives Orphan Drug Designation from the FDA for the treatment of genetic SOD1 ALS

Jul 01, 2019: Copper compound shows further potential as therapy for slowing ALS

Jun 10, 2019: Collaborative Medicinal Development reports that lead drug shows dose-dependent improvement in Parkinson's disease

May 03, 2019: Biogen reports positive data from Phase I/II study of tofersen

May 02, 2019: Experimental drug shows promise for genetic form of ALS

Apr 29, 2019: Voyager Therapeutics Announces New Data on VY-SOD102 at the American Society of Gene and Cell Therapy 2019 Annual Meeting

Apr 17, 2019: Collaborative Medicinal Development wins AU\$1 million grant award from FightMND

Jan 14, 2019: Researchers report positive results from motor neurone disease trial

Jan 07, 2019: Collaborative Medicinal Development reports that lead drug modifies ALS progression

Dec 17, 2018: Biogen provides update on SOD1 phase I Antisense trial

Oct 16, 2018: Voyager Therapeutics announces preclinical data for Amyotrophic Lateral Sclerosis at the Congress of the European Society of Gene and Cell Therapy

Jul 25, 2018: Next-generation ALS drug silences inherited form of the disease in animal models

Jul 16, 2018: Washington University's new ALS therapy in clinical trial stage

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AL-S Pharma AG, H2 2019
Pipeline by Alexion Pharmaceuticals Inc, H2 2019
Pipeline by Alnylam Pharmaceuticals Inc, H2 2019
Pipeline by Apic Bio Inc, H2 2019
Pipeline by AveXis Inc, H2 2019
Pipeline by Biogen Inc, H2 2019
Pipeline by Collaborative Medicinal Development LLC, H2 2019
Pipeline by Priavoid GmbH, H2 2019
Pipeline by ProMIS Neurosciences Inc, H2 2019
Pipeline by Thera Neuropharma Inc, H2 2019
Pipeline by TruCode Gene Repair Inc, H2 2019
Pipeline by Voyager Therapeutics Inc, H2 2019
Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

AL-S Pharma AG
Alexion Pharmaceuticals Inc
Anylam Pharmaceuticals Inc
Apic Bio Inc
AveXis Inc
Biogen Inc
Collaborative Medicinal Development LLC
Priavoid GmbH
ProMIS Neurosciences Inc
Thera Neuropharma Inc
TruCode Gene Repair Inc
Voyager Therapeutics Inc

I would like to order

Product name: Superoxide Dismutase [Cu-Zn] - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/S4D3F7699E49EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S4D3F7699E49EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970